A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction
Abroad (travel likely)RecruitingPHASE1
Conditions
Heart Failure With Reduced Ejection Fraction
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Synergy Healthcare, Bradenton, Florida, United States
Contact: Principal Investigator (Patrick Weston)Nature Coast Clinical Research LLC, Inverness, Florida, United States
Contact: Principal Investigator (Rafik Abadier)Jacksonville Center for Clinical, Jacksonville, Florida, United States
Contact: Principal Investigator (Michael J Koren)Novartis Investigative Site, Montreal, Quebec, Canada
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals